, Volume 41, Issue 5, pp 949–958 | Cite as

Bloodstream infections in patients with or without cancer in a large community hospital

  • M. M. E. M. Bos
  • L. S. Smeets
  • I. Dumay
  • E. de Jonge
Clinical and Epidemiological Study



Cancer is associated with an increased risk of acquiring bloodstream infection (BSIs). Most knowledge on pathogens and outcome are derived from specialised cancer centres. We here sought to compare causative micro-organisms in BSIs in patients with or without cancer in a 600-bed teaching community hospital.


We analysed all positive blood cultures from adult patients between January 2005 and January 2011.


A total of 4,918 episodes of BSI occurred in 2,891 patients, of whom 13.4 % had a diagnosis of cancer (85.5 % with a solid tumour). In both patient groups, Gram-positive isolates were more prevalent (58.7 and 61.4 % in patients with and without cancer, respectively) than Gram-negative isolates (31.8 and 32.3 %, respectively). Amongst Gram-positive organisms, coagulase-negative staphylococci, Staphylococcus aureus and enterococci were the most frequently isolated in both patient groups; in cancer patients, twice as many BSIs were caused by Enterococcus faecalis and E. faecium. Amongst Gram-negative organisms, Escherichia coli was the most common isolate; in cancer patients, twice as many BSIs were caused by Pseudomonas aeruginosa and Enterobacter cloacae. Yeasts were grown from 3.0 % of blood cultures from cancer patients compared to 1.5 % of cultures from non-cancer patients. Cancer patients had a 90-day mortality of 35.8 % following BSI compared to 23.5 % in patients without cancer.


These data demonstrate distinct BSI pathogens and impaired outcomes in patients with cancer in the setting of a large community teaching hospital.


Bloodstream infection Cancer Bacteraemia Fungi Solid tumour 



We are indebted to Wil van Beers (Department of Medical Microbiology, Reinier de Graaf Hospital, Delft, The Netherlands) for the ICT support.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med. 1977;62:731–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Whimbey E, Kiehn TE, Brannon P, Blevins A, Armstrong D. Bacteremia and fungemia in patients with neoplastic disease. Am J Med. 1987;82:723–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33:947–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL. Severe bloodstream infections: a population-based assessment. Crit Care Med. 2004;32:992–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.PubMedCrossRefGoogle Scholar
  6. 6.
    Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28:108–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin. 2001;17:531–70, vii–viii.PubMedCrossRefGoogle Scholar
  10. 10.
    Pizzo PA. Fever in immunocompromised patients. N Engl J Med. 1999;341:893–900.PubMedCrossRefGoogle Scholar
  11. 11.
    Gaytán-Martínez J, Mateos-García E, Sánchez-Cortés E, González-Llaven J, Casanova-Cardiel LJ, Fuentes-Allen JL. Microbiological findings in febrile neutropenia. Arch Med Res. 2000;31:388–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598–601.PubMedCrossRefGoogle Scholar
  14. 14.
    Diekema DJ, Pfaller MA, Jones RN; SENTRY Participants Group. Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997–2000. Int J Antimicrob Agents. 2002;20:412–8.PubMedCrossRefGoogle Scholar
  15. 15.
    González-Barca E, Fernández-Sevilla A, Carratalá J, Grañena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis. 1996;15:291–6.PubMedCrossRefGoogle Scholar
  16. 16.
    [No authors listed]. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med. 1987;317:1692–8.CrossRefGoogle Scholar
  17. 17.
    Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Gonçalves VM. Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center. Eur J Clin Microbiol Infect Dis. 2003;22:137–43.PubMedGoogle Scholar
  18. 18.
    Oliveira AL, de Souza M, Carvalho-Dias VM, Ruiz MA, Silla L, Tanaka PY, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007;39:775–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Yakupogullari Y, Otlu B, Dogukan M, Gursoy C, Korkmaz E, Kizirgil A, et al. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa. Am J Infect Control. 2008;36:e13–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Velasco E, Byington R, Martins CS, Schirmer M, Dias LC, Gonçalves VM. Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect. 2004;10:542–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99:580–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Spanik S, Kukuckova E, Pichna P, Grausova S, Krupova I, Rusnakova V, et al. Analysis of 553 episodes of monomicrobial bacteraemia in cancer patients: any association between risk factors and outcome to particular pathogen? Support Care Cancer. 1997;5:330–3.PubMedCrossRefGoogle Scholar
  23. 23.
    Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006. J Infect Dis. 2008;198:336–43.PubMedCrossRefGoogle Scholar
  24. 24.
    Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect. 2008;14:1041–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Meatherall BL, Gregson D, Ross T, Pitout JD, Laupland KB. Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med. 2009;122:866–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Parkins MD, Gregson DB, Pitout JD, Ross T, Laupland KB. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection. 2010;38:25–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Spanik S, Sufliarsky J, Mardiak J, Sorkovska D, Trupl J, Kunova A, et al. Predictors of mortality in bacteremic cancer patients: retrospective analysis of 64 deaths occurring among 262 bacteremic episodes. Support Care Cancer. 1998;6:291–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulias V, et al. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Infection. 2004;32:65–71.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • M. M. E. M. Bos
    • 1
  • L. S. Smeets
    • 2
  • I. Dumay
    • 1
  • E. de Jonge
    • 3
  1. 1.Division of Medical Oncology, Department of Internal MedicineReinier de Graaf HospitalDelftThe Netherlands
  2. 2.Department of Medical MicrobiologyReinier de Graaf HospitalDelftThe Netherlands
  3. 3.Department of Intensive CareLeiden University Medical CenterLeidenThe Netherlands

Personalised recommendations